Mucus Relief Tablet, Extended Release
NDC 37835-412
Product Information
Mucus Relief (guaifenesin) is a ANDA-approved product labeled by Bi-mart. This medication is used for the temporary relief of coughs caused by the common cold, bronchitis, and other breathing illnesses. It is supplied as a white tablet, extended release for oral administration. This product entry covers the primary NDC 37835-412 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
G;1200
Code Structure Chart
Product Details
What is NDC 37835-412?
What are the uses of this product?
What are Active Ingredients of this product?
- GUAIFENESIN 1200 mg/1 - An expectorant that also has some muscle relaxing action. It is used in many cough preparations.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- GUAIFENESIN (UNII: 495W7451VQ)
- GUAIFENESIN (UNII: 495W7451VQ) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- HYPROMELLOSES (UNII: 3NXW29V3WO)
- CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) (UNII: Z135WT9208)
- SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 310621 - guaiFENesin 1200 MG 12HR Extended Release Oral Tablet
- RxCUI: 310621 - 12 HR guaifenesin 1200 MG Extended Release Oral Tablet
- RxCUI: 310621 - guaifenesin 1200 MG 12 HR Extended Release Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.